NCE Minus one opportunity for Lifyorli

Описание: 𝗡𝗖𝗘-𝟭 𝗔𝗹𝗲𝗿𝘁 | #Lifyorli

A potential First-to-File opportunity you'll want on your radar.

𝗜𝗻𝗱𝗶𝗰𝗮𝘁𝗶𝗼𝗻:
To Treat Platinum-Resistant Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer After One To Three Prior Systemic Treatment Regimens, At Least One Of Which Included Bevacizumab.

𝗘𝘅𝗽𝗹𝗼𝗿𝗲 #Lifyorli 𝗡𝗖𝗘-𝟭 𝗼𝗽𝗽𝗼𝗿𝘁𝘂𝗻𝗶𝘁𝘆:
https://ncegrid.springbiosolution.com...

If you're planning your Para IV strategy, early visibility into NCE-1 timelines can make the difference.

With #NCEGrid, track, monitor, and act on high-value NCE-1 opportunities before the window closes.

𝗪𝗵𝗲𝗻 𝘆𝗼𝘂 𝘁𝗵𝗶𝗻𝗸 𝗣𝗮𝗿𝗮 𝗜𝗩 𝗮𝗻𝗱 𝗮𝗕𝗟𝗔, 𝘁𝗵𝗶𝗻𝗸 𝗡𝗖𝗘 𝗚𝗿𝗶𝗱! – https://lnkd.in/dzZ2cqW8

For deeper insights, connect with us at:
[email protected] / [email protected]

Explore all our NCE-1 videos from 2023: https://lnkd.in/drkvn2bp

#clinicalresearch #Pharmaceuticals #HealthCare #DrugDevelopment #NCE-1 #FirsttoFileGenerics #FirsttoFile #SpringBioSolution #NCEGrid #OvarianCancer #GynecologicOncology